澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ALGORAE PHARMACEUTICALS LTD

0.011

0.000

成交量：31.76萬

成交額：3,493

市值：2,225.38萬

市盈率：-18.33

高：0.011

開：0.011

低：0.011

收：0.011

52周最高：0.024

52周最低：0.007

股本：20.23億

流通股本：10.47億

量比：0.69

換手率：0.03%

股息：- -

股息率：- -

每股收益(TTM):-0.001

每股收益(LYR):0.000

淨資產收益率：-47.38%

總資產收益率：-39.62%

市淨率：11.77

市盈率(LYR):-22.04

資料載入中...

總覽公司新聞資訊公告

Algorae Pharmaceuticals 獲任主權人工智能基礎設施計劃創始成員及啓動合作伙伴

Algorae Pharmaceuticals與Torrent Pharmaceuticals就兩種仿製藥在澳新地區達成許可與供應協議

Algorae製藥與Zydus Lifesciences就10款產品達成澳新市場授權協議

Algorae Pharmaceuticals與彼得·麥卡勒姆癌症中心合作開展第二個AI驅動的藥物協同篩選項目

Algorae製藥公司達成協議將在澳大利亞和新西蘭推出兩款心血管及代謝疾病仿製藥

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/1AI.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"1AI.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"1AI.AU\",,,,,undefined,":{"symbol":"1AI.AU","market":"AU","secType":"STK","nameCN":"ALGORAE PHARMACEUTICALS LTD","latestPrice":0.011,"timestamp":1787638320000,"preClose":0.011,"halted":0,"volume":317563,"delay":0,"changeRate":0,"nameEN":"ALGORAE PHARMACEUTICALS LTD","floatShares":1046585658,"shares":2023070000,"eps":-0.0006,"marketStatus":"未開盤","change":0,"latestTime":"08-25 16:12:00 AEST","open":0.011,"high":0.011,"low":0.011,"amount":3493,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0006,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.011,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":0.6885799071042302,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"1AI.AU","preClose":0.011,"auctionPrice":0.011,"auctionVolume":175000,"auction":3,"marketStatus":"盘后竞价","timestamp":1787551201351}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"1AI.AU\",,,,,undefined,":{"symbol":"1AI.AU","floatShares":1046585658,"roa":"-39.62%","roe":"-47.38%","lyrEps":-0.000499,"volumeRatio":0.6885799071042302,"shares":2023070000,"dividePrice":0,"high":0.011,"amplitude":0,"preClose":0.011,"low":0.011,"week52Low":0.007,"pbRate":"11.77","psRate":"-850.71","week52High":0.024,"institutionHeld":0,"latestPrice":0.011,"eps":-0.0006,"divideRate":0,"volume":317563,"delay":0,"ttmEps":-0.0006,"open":0.011,"prevYearClose":0.014,"prevWeekClose":0.011,"prevMonthClose":0.012,"prevQuarterClose":0.01,"fiveDayClose":0.012,"twentyDayClose":0.012,"sixtyDayClose":0.011,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/1AI.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"1AI.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"1AI.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1199286258","title":"Algorae Pharmaceuticals 獲任主權人工智能基礎設施計劃創始成員及啓動合作伙伴","url":"https://stock-news.laohu8.com/highlight/detail?id=1199286258","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199286258?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 07:04","pubTimestamp":1782687856,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals Ltd 已被指定为一项主权人工智能基础设施计划的创始参与方及启动合作伙伴。这一任命标志着该公司在人工智能与医疗健康交叉领域迈出了重要一步，旨在通过构建国家级的AI基础设施来推动创新。作为启动伙伴，Algorae Pharmaceuticals 将参与该计划的早期开发与实施，有望利用先进的人工智能技术加速其药物研发进程。此举不仅强化了公司在生物科技前沿的地位，也可能为其带来新的增长机遇和战略合作空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["1AI.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169432775","title":"Algorae Pharmaceuticals與Torrent Pharmaceuticals就兩種仿製藥在澳新地區達成許可與供應協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1169432775","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169432775?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 06:55","pubTimestamp":1778021715,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals Ltd宣布与Torrent Pharmaceuticals签署重要合作协议，双方将就两种仿制药分子在澳大利亚和新西兰地区开展许可与供应合作。该协议的签署标志着两家制药企业在澳新市场的战略布局取得实质性进展。通过此项合作，Torrent Pharmaceuticals将获得在澳新地区销售特定仿制药的授权，而Algorae Pharmaceuticals则负责相关产品的供应保障。此次合作涉及的两个仿制药分子将为澳新地区的患者提供更多治疗选择，同时也将增强Algorae Pharmaceuticals在该区域医药市场的影响力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["1AI.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113355794","title":"Algorae製藥與Zydus Lifesciences就10款產品達成澳新市場授權協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1113355794","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113355794?lang=zh_tw&edition=fundamental","pubTime":"2026-04-28 06:39","pubTimestamp":1777329568,"startTime":"0","endTime":"0","summary":"Algorae制药有限公司宣布与印度制药巨头Zydus Lifesciences签署了一项重要合作协议，获得后者10款药品在澳大利亚和新西兰市场的独家经销权。\n此次合作涵盖的治疗领域包括心血管、糖尿病和中枢神经系统药物，将显著扩充Algorae在澳新地区的产品管线。协议约定Zydus将负责药品生产供应，而Algorae则主导当地市场注册申报和商业化推广。\n这项战略合作标志着Algorae正式进军品牌药分销领域，有望通过引入Zydus经过市场验证的成熟产品，快速提升公司在南太平洋地区的市场占有率。双方表示将共同推进这些药品在澳新医疗体系的准入进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","1AI.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116454163","title":"Algorae Pharmaceuticals與彼得·麥卡勒姆癌症中心合作開展第二個AI驅動的藥物協同篩選項目","url":"https://stock-news.laohu8.com/highlight/detail?id=1116454163","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116454163?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 05:58","pubTimestamp":1774821492,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals Ltd (1AI.AU) 已宣布与彼得·麦卡勒姆癌症中心建立合作伙伴关系，共同启动其第二个利用人工智能技术的药物协同筛选项目。此次合作旨在通过先进的计算方法，探索和验证不同药物组合在癌症治疗中的协同效应，以期发现更有效的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","1AI.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199700351","title":"Algorae製藥公司達成協議 將在澳大利亞和新西蘭推出兩款心血管及代謝疾病仿製藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1199700351","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199700351?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 06:04","pubTimestamp":1770588254,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals Ltd宣布已签署一项重要合作协议，计划在澳大利亚与新西兰市场同步上市两款针对心血管疾病和代谢紊乱的通用名药物。\n此次战略布局将显著提升该公司在大洋洲医药市场的竞争力，通过提供高性价比的替代治疗方案，有望缓解当地患者长期用药的经济压力。两款药物的上市也将进一步完善Algorae在慢性病治疗领域的产品矩阵。\n业内人士分析，此次合作将加速仿制药在澳新地区的市场渗透，为Algorae拓展亚太区域业务奠定坚实基础。随着人口老龄化趋势加剧，心血管与代谢疾病药物市场需求持续增长，此举契合区域医疗健康产业的发展方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","1AI.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}